The National Engineering Research Center for Bioengineering Drugs and the Technologies, Institute of Translational Medicine, Nanchang University, Nanchang 330031, China.
School of Life and Science, Nanchang University, Nanchang 330031, China.
Int J Mol Sci. 2021 Jan 19;22(2):970. doi: 10.3390/ijms22020970.
Stem cells including embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and adult stem cells (ASCs) are able to repair/replace damaged or degenerative tissues and improve functional recovery in experimental model and clinical trials. However, there are still many limitations and unresolved problems regarding stem cell therapy in terms of ethical barriers, immune rejection, tumorigenicity, and cell sources. By reviewing recent literatures and our related works, human amnion-derived stem cells (hADSCs) including human amniotic mesenchymal stem cells (hAMSCs) and human amniotic epithelial stem cells (hAESCs) have shown considerable advantages over other stem cells. In this review, we first described the biological characteristics and advantages of hADSCs, especially for their high pluripotency and immunomodulatory effects. Then, we summarized the therapeutic applications and recent progresses of hADSCs in treating various diseases for preclinical research and clinical trials. In addition, the possible mechanisms and the challenges of hADSCs applications have been also discussed. Finally, we highlighted the properties of hADSCs as a promising source of stem cells for cell therapy and regenerative medicine and pointed out the perspectives for the directions of hADSCs applications clinically.
干细胞包括胚胎干细胞(ESCs)、诱导多能干细胞(iPSCs)和成人干细胞(ASCs),能够在实验模型和临床试验中修复/替换受损或退行性组织,并改善功能恢复。然而,干细胞治疗仍然存在许多限制和未解决的问题,如伦理障碍、免疫排斥、致瘤性和细胞来源。通过回顾最近的文献和我们的相关工作,人羊膜来源的干细胞(hADSCs),包括人羊膜间充质干细胞(hAMSCs)和人羊膜上皮干细胞(hAESCs),相对于其他干细胞具有相当大的优势。在这篇综述中,我们首先描述了 hADSCs 的生物学特性和优势,特别是其高多能性和免疫调节作用。然后,我们总结了 hADSCs 在治疗各种疾病的临床前研究和临床试验中的治疗应用和最新进展。此外,还讨论了 hADSCs 应用的可能机制和挑战。最后,我们强调了 hADSCs 作为细胞治疗和再生医学中一种有前途的干细胞来源的特性,并指出了 hADSCs 应用的临床方向的观点。
Int J Mol Sci. 2021-1-19
Differentiation. 2011-2-19
Artif Cells Nanomed Biotechnol. 2018-4-24
Int J Mol Sci. 2020-10-19
Stem Cell Rev Rep. 2025-9-5
Curr Issues Mol Biol. 2025-4-6
J Orthop Surg Res. 2025-3-10
ACS Omega. 2025-2-11
Stem Cell Res Ther. 2020-9-23
Cells. 2020-7-15